Melanoma & Skin Cancer Articles | Page 2

NKTR-214/Nivolumab Combination Shows Promise in Early Study
The combination of the CD122-biased cytokine NKTR-214 and the PD-1 inhibitor nivolumab demonstrated target lesion reductions of 72% for patients with advanced cancers.
New Adjuvant Therapy Era Builds in Melanoma
Researchers are seeking to determine whether the plethora of new therapies that have been introduced in recent years in the advanced and metastatic settings can benefit patients at risk of recurrence earlier in the treatment timeline for melanoma.
Michael A. Postow, MD, discusses the impressive efficacy seen with combining BRAF and MEK inhibitors for patients with melanoma.
Glembatumumab Vedotin Induces 61% DCR in Uveal Melanoma
Glembatumumab vedotin (CDX-011) induced a disease control rate of 61% in patients with metastatic uveal melanoma, despite a low a low objective response rate of 6%.
FDA Grants Adjuvant Dabrafenib/Trametinib Breakthrough Designation for BRAF+ Melanoma
The FDA has awarded the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) a breakthrough therapy designation for the adjuvant treatment of patients with stage III melanoma with a BRAF V600 mutation following complete resection.
Adjuvant Nivolumab/Ipilimumab Sustains RFS Benefit in Melanoma at 3 Years
The combination of adjuvant nivolumab and ipilimumab led to a 3-year relapse-free survival rate of 71% in patients with high-risk resected stage IIIC/IV melanoma.
Adjuvant Dabrafenib/Trametinib RFS Benefit Persists Across Melanoma Subgroups
A doubling in 3-year relapse-free survival rates remained consistent across patient subgroups treated with dabrafenib and trametinib, when compared with placebo, for patients with BRAF-mutant stage III melanoma.
Nivolumab/Ipilimumab Combo Active for Melanoma Brain Mets
The combination of nivolumab and ipilimumab showed an intracranial response rate of 46% for asymptomatic patients with melanoma brain metastases who had not received prior local therapy to the brain.
Immune-Stimulator Boosts Pembrolizumab in Melanoma Patients With
Adding the immune stimulator ImmunoPulse IL-12 to pembrolizumab (Keytruda) produced promising activity among patients with melanoma identified as unlikely responders to anti–PD-1 therapies.
Triplet Therapy on Horizon for BRAF+ Melanoma
The combination of anti–PD-1/PD-L1 immunotherapy with BRAF plus MEK inhibitors is advancing rapidly following early promising phase results for patients with BRAF-mutant advanced melanoma.
Publication Bottom Border
Border Publication